Dimensional Fund Advisors LP Buys 320,724 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Dimensional Fund Advisors LP grew its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 18.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,035,070 shares of the specialty pharmaceutical company’s stock after buying an additional 320,724 shares during the period. Dimensional Fund Advisors LP’s holdings in Jazz Pharmaceuticals were worth $250,619,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Bessemer Group Inc. increased its position in Jazz Pharmaceuticals by 0.3% during the 4th quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company’s stock valued at $3,317,000 after purchasing an additional 92 shares during the period. CIBC Asset Management Inc increased its position in shares of Jazz Pharmaceuticals by 5.2% during the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock worth $243,000 after buying an additional 97 shares during the period. Synovus Financial Corp raised its stake in Jazz Pharmaceuticals by 0.5% during the fourth quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company’s stock worth $2,365,000 after buying an additional 100 shares during the last quarter. Quadrant Capital Group LLC lifted its holdings in Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 101 shares during the period. Finally, UMB Bank n.a. boosted its position in Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 129 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on JAZZ shares. Truist Financial lifted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Morgan Stanley restated an “overweight” rating and set a $183.00 price target (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Finally, Barclays reaffirmed an “overweight” rating and issued a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $187.71.

Jazz Pharmaceuticals Trading Down 2.4 %

NASDAQ:JAZZ opened at $100.34 on Tuesday. Jazz Pharmaceuticals plc has a 52 week low of $95.49 and a 52 week high of $148.06. The firm has a 50-day moving average price of $126.90 and a two-hundred day moving average price of $122.44. The firm has a market cap of $6.09 billion, a price-to-earnings ratio of 14.13, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares in the company, valued at $53,785,088.64. The trade was a 0.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares of the company’s stock, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,736 shares of company stock worth $4,023,305. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.